Drugs / Telatinib
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03175497 | Jul 2017 → Aug 2018 | cancer | Taizhou EOC Pharma Co., Ltd. | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT04798781 | Jul 2021 → Feb 2024 | gastric cancer, hepatocellular carcinoma | Andrew Hendifar, MD | Completed | No outcome recorded |
| Phase 2 | NCT00952497 | Jun 2009 → Oct 2011 | gastric cancer | ACT Biotech, Inc | Completed | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 2 | NCT03817411 Comparator | Jan 2019 → Mar 2020 | gastric cancer | Taizhou EOC Pharma Co., Ltd. | Unknown | No outcome recorded |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Telatinib | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03817411 ↗ |
| Known as | BAY 57-9352 | ChEMBL registry synonym — accepted as the source's own label CHEMBL2079588 ↗ |
| Action | Inhibit | “Vascular endothelial growth factor receptor 2 inhibitor” CHEMBL2079588 ↗3“Vascular endothelial growth factor receptor 3 inhibitor” CHEMBL2079588 ↗ “Platelet-derived growth factor receptor beta inhibitor” CHEMBL2079588 ↗ “Stem cell growth factor receptor inhibitor” CHEMBL2079588 ↗ |
| Modality | Small molecule | — CHEMBL2079588 ↗ |
| Route | Oral | “Telatinib (3 tablets) will be administered orally” NCT00952497 ↗ |
| Target | FLT4 | “Vascular endothelial growth factor receptor 3 inhibitor” CHEMBL2079588 ↗ |
| Target | KDR | “Vascular endothelial growth factor receptor 2 inhibitor” CHEMBL2079588 ↗ |
| Target | KIT | “Stem cell growth factor receptor inhibitor” CHEMBL2079588 ↗ |
| Target | PDGFRB | “Platelet-derived growth factor receptor beta inhibitor” CHEMBL2079588 ↗ |